Boston Therapeutics offers details on $5.3 million placement of units

Company sells units of one share and one half-share warrant in deal

By Devika Patel

Knoxville, Tenn., Oct. 4 - Boston Therapeutics, Inc. gave further details about the $1.77 million fourth and final tranche of a $5.3 million private placement of units that settled on Sept. 30 in an 8-K filed Friday with the Securities and Exchange Commission. The deal raised $2 million on July 23, $848,468 on Aug. 6 and $678,135 on Aug. 30.

The company sold 17,659,035 units of one common share and one half-share warrant at $0.30 per unit. It sold 6,666,660 in the first tranche, 2,828,226 units in the second tranche, 2,260,449 units in the third tranche and 5,903,700 units in the fourth tranche.

Each whole warrant is exercisable at $0.50. The strike price is a 9.09% discount to $0.55, the July 22 closing share price.

The Manchester, N.H., company makes and commercializes therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases.

Issuer:	Boston Therapeutics, Inc.
Issue:	Units of one common share and one half-share warrant
Amount:	$5,297,711
Units:	17,659,035
Price:	$0.30
Warrants:	One half-share warrant per unit
Warrant strike price:	$0.50
Settlement date:	July 23 (for $2 million), Aug. 6 (for $848,468), Aug. 30 (for $678,135), Sept. 30 (for $1,771,110)
Stock symbol:	OTCBB: BTHE
Stock price:	$0.55 at close July 22
Market capitalization:	$21.32 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.